New insights into estrogenic regulation of O⁶-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: Co-degradation of ER-α and MGMT proteins by fulvestrant or O⁶-benzylguanine indicates fresh avenues for therapy

Abstract

Endocrine therapy using estrogen receptor-α (ER-α) antagonists for attenuating horm2one-driven cell proliferation is a major treatment modality for breast cancers. To exploit any DNA repair deficiencies associated with endocrine therapy, we investigated the functional and physical interactions of ER-α with O⁶-methylguanine DNA methyltransferase (MGMT), a unique DNA repair protein that confers tumor resistance to various anticancer alkylating agents. The ER-α -positive breast cancer cell lines (MCF-7, T47D) and ER- negative cell lines (MDAMB-468, MDAMB-231), and established inhibitors of ER-α and MGMT, namely, ICI-182,780 (Faslodex) and O⁶-benzylguanine, respectively, were used to study MGMT- ER interactions. The MGMT gene promoter was found to harbor one full and two half estrogen-responsive elements (EREs) and two antioxidant-responsive elements (AREs). MGMT expression was upregulated by estrogen, downregulated by tamoxifen in Western blot and promoter-linked reporter assays. Similarly, both transient and stable transfections of Nrf-2 (nuclear factor-erythroid 2-related factor-2) increased the levels of MGMT protein and activity 3 to 4-fold reflecting novel regulatory nodes for this drug-resistance determinant. Of the different ER-α antagonists tested, the pure anti-estrogen fulvestrant was most potent in inhibiting the MGMT activity in a dose, time and ER-α dependent manner, similar to O⁶-benzylguanine. Interestingly, fulvestrant exposure led to a degradation of both ER-α and MGMT proteins and O⁶-benzylguanine also induced a specific loss of ER-α and MGMT proteins in MCF-7 and T47D breast cancer cells with similar kinetics. Immunoprecipitation revealed a specific association of ER-α and MGMT proteins in breast cancer cells. Furthermore, silencing of MGMT gene expression triggered a decrease in the levels of both MGMT and ER-α proteins. The involvement of proteasome in the drug-induced degradation of both proteins was also demonstrated. Fulvestrant enhanced the cytotoxicity of MGMT-targeted alkylating agents, namely, temozolomide and BCNU by 3 to 4-fold in ER-α positive cells, but not in ER–negative cells. We conclude that MGMT and ER-α proteins exist as a complex and are co-targeted for ubiquitin-conjugation and subsequent proteasomal degradation. The findings offer a clear rationale for combining alkylating agents with endocrine therapy.

Keywords

estrogen signaling / MGMT DNA repair / ubiquitin-proteasome pathway / breast cancer / anti-estrogens

References

[1] Heldring N, Pike A, Andersson S, Estrogen receptors: how do they signal and what are their targets[J]. Physiol Rev, 2007, 87(3): 905–931.

[2] Klinge CM, Jernigan SC, Mattingly KA, Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors[J]. J Mol Endocrinol, 2004, 33(2): 387–410.

[3] Dechering K, Boersma C, Mosselman S. Estrogen receptors alpha and beta: two receptors of a kind[J]? Curr Med Chem, 2000, 7(5): 561–576.

[4] Huang B, Omoto Y, Iwase H, Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer[J]. Proc Natl Acad Sci USA, 2014, 111(5): 1933–1938.

[5] Masood S. Use of monoclonal antibody for assessment of estrogen and progesterone receptors in malignant effusions[J]. Diagn Cytopathol, 1992, 8(2): 161–166.

[6] Sommer S, Fuqua SA. Estrogen receptor and breast cancer[J]. Semin Cancer Biol, 2001, 11(5): 339–352.

[7] Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance[J]. Nat Rev Cancer, 2002, 2(2): 101–112.

[8] Burstein HJ, Temin S, Anderson H, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update[J]. J Clin Oncol, 2014, 32(21): 2255–2269.

[9] Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer[J]. Breast Cancer (Dove Med Press), 2014, 6: 29–36.

[10] McDonnell DP, Wardell SE, Norris JD. Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer[J]. J Med Chem, 2015, 58(12): 4883–4887.

[11] Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action[J]. Br J Cancer, 2004, 90(Suppl 1): S2–S6.

[12] Miller K. Estrogen and DNA damage: the silent source of breast cancer[J]? J Natl Cancer Inst, 2003, 95(2): 100–102.

[13] Caldon CE. Estrogen signaling and the DNA damage response in hormone dependent breast cancers[J]. Front Oncol, 2014, 4: 106

[14] Walerych D, Napoli M, Collavin L, The rebel angel: mutant p53 as the driving oncogene in breast cancer[J]. Carcinogenesis, 2012, 33(11): 2007–2017.

[15] Allison KH. Molecular pathology of breast cancer: what a pathologist needs to know[J]. Am J Clin Pathol, 2012, 138(6): 770–780.

[16] Cayre A, Penault-Llorca F, De Latour M, O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma[J]. Int J Oncol, 2002, 21(5): 1125–1131.

[17] Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases[J]. Mutat Res, 2000, 462(2-3): 83–100.

[18] Mishina Y, Duguid EM, He C. Direct reversal of DNA alkylation damage[J]. Chem Rev, 2006, 106(2): 215–232.

[19] Gerson SL. Clinical relevance of MGMT in the treatment of cancer[J]. J Clin Oncol, 2002, 20(9): 2388–2399.

[20] Kaina B, Margison GP, Christmann M. Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy[J]. Cell Mol Life Sci, 2010, 67(21): 3663–3681.

[21] Srivenugopal KS, Yuan XH, Friedman HS, Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea[J]. Biochemistry, 1996, 35(4): 1328–1334.

[22] Srivenugopal KS, Rawat A, Niture SK, Posttranslational regulation of O6-methylguanine-DNA methyltransferase (MGMT) and new opportunities for treatment of brain cancers.See comment in PubMed Commons below[J]. Mini Rev Med Chem, 2016, 16(6): 455–464.

[23] Chang BD, Beattie CW, Hussain RA, Estrous cycle modulation of O6-alkylguanine-DNA alkyltransferase expression in rat mammary epithelial cells[J]. Cancer Lett, 1993, 75(1): 11–18.

[24] Dutta-Choudhury TA, Bak BH, Guzman RC. Cellular levels of O6-methylguanine-DNA methyltransferase in mammary epithelial cells and liver from virgin, pregnant and pituitary grafted mice[J]. Carcinogenesis, 1991, 12(10): 1795–1800.

[25] Henderson BE, Feigelson HS. Hormonal carcinogenesis[J]. Carcinogenesis, 2000, 21(3): 427–433.

[26] Teo AK, Oh HK, Ali RB, The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage[J]. Mol Cell Biol, 2001, 21(20): 7105–7114.

[27] Musarrat J, Wilson JA, Abou-Issa H, O(6)-alkylguanine DNA alkyltransferase activity levels in normal, benign and malignant human female breast[J]. Biochem Biophys Res Commun, 1995, 208(2): 688–696.

[28] Bobustuc GC, Smith JS, Maddipatla S, MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy[J]. Mol Med, 2012, 18(8): 913–929.

[29] Citron M, Schoenhaus M, Rothenberg H, O6-methylguanine-DNA methyltransferase in normal and malignant tissue of the breast[J]. Cancer Invest, 1994, 12(6): 605–610.

[30] Isono S, Fujishima M, Azumi T, O(⁶)-methylguanine-DNA methyltransferase as a prognostic and predictive marker for basal-like breast cancer treated with cyclophosphamide-based chemotherapy[J]. Oncol Lett, 2014, 7(6): 1778–1784.

[31] Hansen RJ, Ludeman SM, Paikoff SJ, Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals[J]. DNA Repair (Amst), 2007, 6(8): 1145–1154.

[32] Niture SK, Doneanu CE, Velu CS, Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry[J]. Biochem Biophys Res Commun, 2005, 337(4): 1176–1184.

[33] Paranjpe A, Zhang R, Ali-Osman F, Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage[J]. Carcinogenesis, 2014, 35(3): 692–702.

[34] Klinge CM. Estrogen receptor interaction with estrogen response elements[J]. Nucleic Acids Res, 2001, 29(14): 2905–2919.

[35] Velu CS, Niture SK, Doneanu CE, Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress[J]. Biochemistry, 2007, 46(26): 7765–7780.

[36] Harada H, Nakagawa K, Saito M, Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells[J]. Cancer Lett, 2003, 191(1): 109–119.

[37] Sato H, Yazawa T, Suzuki T, Growth regulation via insulin-like growth factor binding protein-4 and-2 in association with mutant K-ras in lung epithelia[J]. Am J Pathol, 2006, 169(5): 1550–1566.

[38] Gross JA, Fiori LM, Labonté B, Effects of promoter methylation on increased expression of polyamine biosynthetic genes in suicide[J]. J Psychiatr Res, 2013, 47(4): 513–519.

[39] Jiang C, Guo J, Wang Z, Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells[J]. Breast Cancer Res, 2007, 9(6): R77.

[40] Niture SK, Rao US, Srivenugopal KS. Chemopreventative strategies targeting the MGMT repair protein: augmented expression in human lymphocytes and tumor cells by ethanolic and aqueous extracts of several Indian medicinal plants[J]. Int J Oncol, 2006, 29(5): 1269–1278.

[41] Ali-Osman F, Rairkar A, Young P. Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells[J]. Cancer Biochem Biophys, 1995, 14(4): 231–241.

[42] Kuo CC, Liu JF, Shiah HS, Tamoxifen accelerates proteasomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells[J]. Int J Cancer, 2007, 121(10): 2293–2300.

[43] Harris LC, Potter PM, Tano K, Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene[J]. Nucleic Acids Res, 1991, 19(22): 6163–6167.

[44] Biswas T, Ramana CV, Srinivasan G, Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone[J]. Oncogene, 1999, 18(2): 525–532.

[45] Niture SK, Velu CS, Smith QR, Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines[J]. Carcinogenesis, 2007, 28(2): 378–389.

[46] Al-Sawaf O, Clarner T, Fragoulis A, Nrf2 in health and disease: current and future clinical implications[J]. Clin Sci (Lond), 2015, 129(12): 989–999.

[47] Kansanen E, Kuosmanen SM, Leinonen H, The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer[J]. Redox Biol, 2013, 1(1): 45–49.

[48] Yao Y, Brodie AM, Davidson NE, Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer[J]. Breast Cancer Res Treat, 2010, 124(2): 585–591.

[49] Carlson RW. The history and mechanism of action of fulvestrant[J]. Clin Breast Cancer, 2005, 6(Suppl 1): S5–S8.

[50] Yeh WL, Shioda K, Coser KR, Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase[J]. PLoS ONE, 2013, 8(4): e60889.

[51] Wijayaratne AL, McDonnell DP. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators[J]. J Biol Chem, 2001, 276(38): 35684–35692.

[52] Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation[J]. Mol Endocrinol, 1999, 13(9): 1522–1534.

[53] de la Cruz J, Karbstein K, Woolford JL Jr. Functions of ribosomal proteins in assembly of eukaryotic ribosomes in vivo[J]. Annu Rev Biochem, 2015, 84: 93–129.

[54] Méndez-Hernández LE, Pérez-Mejía AE, Lara-Chacón B, Gpn1 and Gpn3 associate tightly and their protein levels are mutually dependent in mammalian cells[J]. FEBS Lett, 2014, 588(21): 3823–3829.

[55] Kim DH, Sabatini DM. Raptor and mTOR: Subunits of a nutrient-sensitive complex[J]. In: TOR target of rapamycin. 2004, Thomas G. et al., Eds. Springer-Verlag, Berlin Heidelberg, 260–269.

[56] Carberry K, Wiesenfahrt T, Geisler F, The novel intestinal filament organizer IFO-1 contributes to epithelial integrity in concert with ERM-1 and DLG-1[J]. Development, 2012, 139(10): 1851–1862.

[57] Philip S, Swaminathan S, Kuznetsov SG, Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications[J]. Cancer Res, 2008, 68(23): 9973–9981.

Acknowledgements

This work was supported by grants from the Cancer Prevention Research Institute of Texas (RP130266), the Carson-Leslie Foundation and the Association for Research of Childhood Cancer, all to K.S.S. We thank Drs. Sankar Mitra (Univ. of Texas Medical Branch) and Anil Jaiswal (Univ. of Maryland) for MGMT promoter constructs and Nrf2 expression vector respectively.

RIGHTS & PERMISSIONS

2016 2016 by the Journal of Biomedical Research. All rights reserved.